1-4 of 4
Margaret K. Callahan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma

Maryam Pourmaleki, Caitlin J. Jones, Charlotte E. Ariyan, Zheng Zeng, Mono Pirun, Daniel A. Navarrete, Yanyun Li, Mianlei Zhang, Subhiksha Nandakumar, Carl Campos, Saad Nadeem, David S. Klimstra, Claire F. Temple-Oberle, Thomas Brenn, Evan J. Lipson, Kara M. Schenk, Julie E. Stein, Janis M. Taube, Michael G. White, Raymond Traweek, Jennifer A. Wargo, John M. Kirkwood, Billel Gasmi, Stephanie L. Goff, Alex D. Corwin, Elizabeth McDonough, Fiona Ginty, Margaret K. Callahan, Andrea Schietinger, Nicholas D. Socci, Ingo K. Mellinghoff, Travis J. Hollmann
Journal: Cancer Immunology Research
Cancer Immunol Res (2022) 10 (3): 303–313.
https://doi.org/10.1158/2326-6066.CIR-21-1083
Published: 01 March 2022
View article titled, Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma
Open the PDF for Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract PR01: Mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients

Roberta Zappasodi, Cynthia Sirard, Yanyun Li, Sadna Budhu, Moshen Abu-Akeel, Cailian Liu, Xia Yang, Hong Zhong, Walter Newman, Jinjin Qi, Phillip Wong, David Schaer, Henry Koon, Vamsidhar Velcheti, Michael Postow, Margaret K Callahan, Jedd D. Wolchok, Taha D. Merghoub
Journal: Cancer Immunology Research
Cancer Immunol Res (2019) 7 (2_Supplement): PR01.
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-PR01
Published: 01 February 2019
View article titled, Abstract PR01: Mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients
Journal Articles

Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors

Margaret K. Callahan, Kunle Odunsi, Mario Sznol, John Nemunaitis, Patrick A. Ott, Patrick Dillon, Reva Schneider, Andrew Park, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus, Jedd D. Wolchok
Journal: Cancer Immunology Research
Cancer Immunol Res (2019) 7 (2_Supplement): A006.
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-A006
Published: 01 February 2019
View article titled, Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Journal Articles

Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor

Margaret K. Callahan, Gregg Masters, Christine A. Pratilas, Charlotte Ariyan, Jessica Katz, Shigehisa Kitano, Valerie Russell, Ruth Ann Gordon, Shachi Vyas, Jianda Yuan, Ashok Gupta, Jon M. Wigginton, Neal Rosen, Taha Merghoub, Maria Jure-Kunkel, Jedd D. Wolchok
Journal: Cancer Immunology Research
Cancer Immunol Res (2014) 2 (1): 70–79.
https://doi.org/10.1158/2326-6066.CIR-13-0160
Published: 02 January 2014
View article titled, Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
Open the PDF for Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor in another window
Includes: Supplementary data